中重度溃疡性结肠炎的生物制剂治疗与手术治疗研究进展  

Research progress in biological agent treatment and surgical treatment of moderate to severe ulcerative colitis

作　　者：陈玉洁(综述) 郭志国(审校) CHEN Yu-jie;GUO Zhi-guo(Department of Gastroenterology,Suzhou Hospital Affiliated to Anhui Medical University(Suzhou Municipal Hospital),Suzhou 234000,Anhui,CHINA)

机构地区：[1]安徽医科大学附属宿州医院(宿州市立医院)消化内科,安徽宿州234000

出　　处：《海南医学》2023年第9期1357-1360,共4页Hainan Medical Journal

基　　金：安徽省高等学校省级质量工程项目课题(编号:2020jyxm2058)。

摘　　要：溃疡性结肠炎(ulcerative colitis,UC)是一种慢性炎症性肠道疾病,可累及结肠的任何部位,从直肠黏膜炎症开始,并持续向近端延伸。其中急性重度UC发生危及生命的并发症导致紧急结肠切除术的风险增加,常需使用免疫调节剂或生物制剂治疗,包括环孢素、TNF-α拮抗剂、维得利珠单抗、乌司奴单抗及Janus激酶(JAK)抑制剂等,以减轻手术风险。中重度UC最佳治疗策略的选择是复杂的,对于不同治疗方法的疗效和安全性的比较临床数据有限,导致实践中存在相当大的差异。因此本文目的是回顾最新临床文献,以阐述中重度UC的治疗策略和决策影响因素。Ulcerative colitis(UC)is a chronic inflammatory intestinal disease that can involve any part of the colon,which starts with inflammation of the rectal mucosa,and continues to extend proximally.Acute severe UC with life-threatening complications increases the risk of emergency colectomy,and immunomodulators or biologics such as cyclosporine,tumor necrosis factor alpha(TNF-α)antagonists,vedolizumab,ustekinumab,and Janus kinase(JAK)inhibitors are commonly used to reduce the operational risk.The optimal treatment strategy for moderate to severe UC has yet to be identified because there are limited comparative studies and clinical data on the efficacy and safety profiles of different treatment regimens,leading to considerable variation in clinical practice.This paper reviews recent clinical studies on the topic,aiming to reveal potential factors that influence the treatment strategy adopted and the decisions made by clinicians when treating moderate to severe UC.

关 键 词：中重度溃疡性结肠炎 生物制剂 JAK抑制剂 手术 内外科疗法 

分 类 号：R574.62[医药卫生—消化系统]